Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Switching to sorafenib treatment significantly improved OS and TTDP in patients with intermediate-stage HCC who were refractory to TACE. These finding highlights sorafenib's potential as an effective alternative for managing disease progression in patients unresponsive to TACE, offering a valuable treatment option in this challenging clinical scenario.
Authors
- Heba Abdelhalim
- Mohammed Atef (ORCID: https://orcid.org/0000-0001-9439-3404)
- Sally Waheed Elkhadry (ORCID: https://orcid.org/0000-0001-9305-3045)
- Eman Rewisha
- Mohamed Akl Rady (ORCID: https://orcid.org/0000-0002-7224-4165)
- Reham Ashour (ORCID: https://orcid.org/0009-0007-5470-5531)
Institutions
- Menoufia University (EG)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1186/s12885-024-13199-1
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Science and Technology Development Fund